// STATE LEGISLATION TRACKER

Minnesota HF 4188: Commerce policy bill.

⚖️ NEUTRAL for peptide users 👤 LOW user impact 📜 Status: Signed

State: Minnesota
Bill: HF 4188
Session: 2025-2026
Filed: 2026-03-12
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Minnesota HF4188 is a signed commerce policy law focused on insurance, consumer protection, financial products, unclaimed property, and prescription-drug cost transparency. It does not directly regulate compounded peptides, off-label prescribing, telehealth peptide care, naturopathic or NP scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No direct change to access for compounded peptides
No new peptide-specific prescribing or telehealth rule found
No apparent change to NP or naturopathic scope for peptides
Health plans must report more prescription drug cost data
Drug affordability review rules are adjusted, but not peptide-specific

What to Watch For

Note This is now law in Minnesota as Chapter 124, with various effective dates.

✓

Opportunity More prescription drug cost and supply-chain data may improve price transparency over time.

Note The bill does not appear to touch FDA 503A or 503B compounding rules.

Note No controlled-substance or prescription-monitoring change was found in the bill text.

Where the Bill Stands

The bill passed both chambers, was approved by the governor on May 27, 2026, and was filed as Chapter 124.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws